Steven Pieper Xeris Biopharma Holdings, Inc. (XERS) insider trading activity

Steven Pieper is Officer of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 1.23 Million shares of XERS, which is worth approximately $4.56 Million. The most recent transaction as insider was on Jan 31, 2025, when has been sold 177,200 shares (Common Stock) at a price of $3.56 per share, resulting in proceeds of $630,832. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.23M

13.34% 3M change

14.23% 12M change

Total Value Held $4.56 Million

Steven Pieper Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 31 2025	SELL Payment of exercise price or tax liability	$630,832 $3.56 p/Share	177,200 Reduced 12.57%	1,232,561 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	185,000 Added 11.54%	1,417,561 Common Stock
Jan 03 2025	SELL Payment of exercise price or tax liability	$115,732 $3.61 p/Share	32,059 Reduced 2.22%	1,409,761 Common Stock
Nov 22 2024	BUY Exercise of conversion of derivative security	$30,198 $1.55 p/Share	19,483 Added 1.33%	1,441,820 Common Stock
Jul 28 2024	SELL Payment of exercise price or tax liability	$38,541 $2.61 p/Share	14,767 Reduced 1.03%	1,422,337 Common Stock
Jan 31 2024	SELL Payment of exercise price or tax liability	$272,445 $2.46 p/Share	110,750 Reduced 7.16%	1,437,104 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	450,000 Added 21.67%	1,626,912 Common Stock
Jan 29 2024	SELL Payment of exercise price or tax liability	$11,648 $2.66 p/Share	4,379 Reduced 0.28%	1,547,854 Common Stock
Jan 03 2024	SELL Payment of exercise price or tax liability	$51,670 $2.24 p/Share	23,067 Reduced 1.46%	1,552,233 Common Stock
Nov 20 2023	BUY Open market or private purchase	$54,600 $1.95 p/Share	28,000 Added 2.32%	1,176,912 Common Stock
Jul 28 2023	SELL Payment of exercise price or tax liability	$25,805 $2.53 p/Share	10,200 Reduced 0.64%	1,575,300 Common Stock
Jan 31 2023	SELL Payment of exercise price or tax liability	$964 $1.24 p/Share	778 Reduced 0.05%	1,585,500 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	750,000 Added 39.5%	1,148,912 Common Stock
Jan 29 2023	SELL Payment of exercise price or tax liability	$4,523 $1.26 p/Share	3,590 Reduced 0.23%	1,586,278 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$25,835 $1.12 p/Share	23,067 Reduced 1.43%	1,589,868 Common Stock
Jul 28 2022	SELL Payment of exercise price or tax liability	$13,966 $1.43 p/Share	9,767 Reduced 0.6%	1,612,935 Common Stock
Jan 31 2022	SELL Payment of exercise price or tax liability	$1,582 $2.11 p/Share	750 Reduced 0.05%	1,622,702 Common Stock
Jan 29 2022	SELL Payment of exercise price or tax liability	$7,300 $2.11 p/Share	3,460 Reduced 0.21%	1,623,452 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	200,000 Added 33.97%	388,834 Common Stock
Nov 10 2021	BUY Open market or private purchase	$50,000 $2.0 p/Share	25,000 Added 12.01%	183,108 Common Stock
Oct 05 2021	BUY Grant, award, or other acquisition	-	158,108 Added 50.0%	158,108 Common Stock

Also insider at

XERS

XERIS PHARMACEUTICALS INC Healthcare

Chief Financial Officer

Steven Pieper

Officer

Chicago, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XERS shares.

Notify only if

Value

Insider Trading

Get notified when an Xeris Biopharma Holdings, Inc. insider buys or sells XERS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Xeris Biopharma Holdings, Inc.

Track Activities on XERS

Account